# Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

> **NCT00886743** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 19 (actual)

## Conditions studied

- Severe Thrombocytopenia

## Interventions

- **DRUG:** oprelvekin

## Key facts

- **NCT ID:** NCT00886743
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Business reason, Pfizer's requested withdrawal of the Biologics License Application (BLA) . This study is not being discontinued for efficacy or safety reason
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00886743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00886743, "Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00886743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*